Searchable abstracts of presentations at key conferences in endocrinology

ea0016pl8 | Central regulation of appetite and body weight – the role of peripheral signals | ECE2008

Central regulation of appetite and body weight: the role of peripheral signals

Bruning Jens

The ever-growing obesity epidemic puts an enormous burden on our societies. The need for the development of novel therapeutic interventions necessitates the exact understanding of the underlying regulatory principles in energy homeostasis. Over the last 10 years, the hormonal and nutritional factors communicating the energy state of the body to the central nervous system to adapt caloric intake and energy expenditure have rapidly extended our understanding on the mechanisms co...

ea0063pl7 | Control of Integrative Physiology by the Melanocortin Circuitry | ECE2019

Control of Integrative Physiology by the Melanocortin Circuitry

Bruning Mr. Jens Claus

Proopiomelanocortin (POMC)- and agouti related peptide (AgRP)-expressing neurons in the arcuate nucleus of the hypothalamus (ARH) are critical regulators of food intake and energy homeostasis. They rapidly integrate the energy state of the organism through sensing fuel availability via hormones, nutrient components and even rapidly upon sensory food perception. Importantly, they not only regulate feeding responses, but numerous autonomic responses including glucose and lipid m...

ea0041oc5.4 | Neuroendocrinology | ECE2016

CNS IL-6 Trans-Signaling is enhanced in obese mice to improve anorexigenic and glucoregulatory effects of IL-6

Timper Katharina , Denson Jesse , Steculorum Sophie Marie , Rose-John Stefan , Wunderlich Frank Thomas , Bruning Jens C

Introduction: Interleukin (IL)-6 can activate signal transducer and activator of transcription (STAT)3-dependent signaling similar to leptin in neurons. Here we demonstrate that central application of IL-6 suppresses feeding and improves glucose tolerance in mice. Furthermore, we found that central IL-6 trans-signaling is enhanced in obese mice to improve anorexigenic and glucoregulatory effects of IL-6.Methods/design: Glucose tolerance and insulin sensi...

ea0049gp105 | Diabetes therapy & complications 2 | ECE2017

Ceramide synthase 6 inhibition as a novel therapeutic approach for obesity and type 2 diabetes

Bielohuby Maximilian , Prakash Surya , Brunner Bodo , Pfenninger Anja , Werner Ulrich , Turpin-Nolan Sarah , Bruning Jens , Tennagels Norbert

Excess consumption of saturated fatty acids may lead to an increased production of ceramides that contribute to development of insulin resistance and type 2 diabetes. Substantial research demonstrated that inhibition of ceramide biosynthesis ameliorates atherosclerosis, hepatic steatosis, insulin resistance and obesity. However, as ceramides and their sphingolipid products are involved in multiple fundamental cellular processes, concerns exist about possible risks or adverse e...

ea0037s7.2 | Novel mechanisms of central weight regulation | ECE2015

Regulation of hypothalamic development by maternal nutrition

Vogt Merly , Paeger Lars , Hess Simon , Steculorum Sophie , Neupert Susanne , Predel Reinhard , Kloppenburg Peter , Horvath Tamas , Bruning Jens

In light of the ever-increasing incidences of obesity and T2DM, development of novel therapeutic or preventative measures to combat these epidemics is of utmost importance. Identification of a causal relationship between an altered maternal metabolic homeostasis and an increased propensity for the unborn child to develop metabolic disorders throughout lifetime has shifted considerable amount of attention towards understanding the underlying cellular and molecular alterations. ...

ea0041gp40 | Bone & Calcium Homeostasis | ECE2016

Severe osteomalacia caused by a phosphaturic mesenchymal tumor secreting fibroblast growth factor 23: a case report

Ravarani Lisa , Faust Michael , Quaas Alexander , Bludau Marc , Schmidt Matthias , Allendorf Inka , Topuzoglu-Muller Tengu , Hanszen Ruth , Schary Oliver , Bruning Jens C

Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic syndrome clinically presenting with recurring fractures, muscular weakness and pain. Laboratory values of affected patients are characterized by renal phosphate wasting and hypophosphatemia caused by an overexpression of fibroblast growth factor 23 (FGF- 23), a hormone belonging to the group of phosphatonins regulating phosphate and vitamin D homeostasis. Pathologically, it is secreted especially by small (and ...